Prophylactic efficacy of a human monoclonal antibody against MERS-CoV in the common marmoset.
Identifieur interne : 000414 ( PubMed/Checkpoint ); précédent : 000413; suivant : 000415Prophylactic efficacy of a human monoclonal antibody against MERS-CoV in the common marmoset.
Auteurs : Emmie De Wit [États-Unis] ; Friederike Feldmann [États-Unis] ; Eva Horne [États-Unis] ; Atsushi Okumura [États-Unis] ; Elisabetta Cameroni [Suisse] ; Elaine Haddock [États-Unis] ; Greg Saturday [États-Unis] ; Dana Scott [États-Unis] ; Robin Gopal [Royaume-Uni] ; Maria Zambon [Royaume-Uni] ; Davide Corti [Suisse] ; Heinz Feldmann [États-Unis]Source :
- Antiviral research [ 1872-9096 ] ; 2019.
Descripteurs français
- KwdFr :
- Administration par voie intraveineuse, Animaux, Anticorps antiviraux (administration et posologie), Anticorps antiviraux (immunologie), Anticorps monoclonaux (administration et posologie), Anticorps monoclonaux (immunologie), Anticorps neutralisants (administration et posologie), Anticorps neutralisants (immunologie), Callithrix, Coronavirus du syndrome respiratoire du Moyen-Orient, Humains, Infections à coronavirus (), Modèles animaux de maladie humaine, Poumon (), Poumon (anatomopathologie), Poumon (virologie).
- MESH :
- administration et posologie : Anticorps antiviraux, Anticorps monoclonaux, Anticorps neutralisants.
- anatomopathologie : Poumon.
- immunologie : Anticorps antiviraux, Anticorps monoclonaux, Anticorps neutralisants.
- virologie : Poumon.
- Administration par voie intraveineuse, Animaux, Callithrix, Coronavirus du syndrome respiratoire du Moyen-Orient, Humains, Infections à coronavirus, Modèles animaux de maladie humaine, Poumon.
English descriptors
- KwdEn :
- Administration, Intravenous, Animals, Antibodies, Monoclonal (administration & dosage), Antibodies, Monoclonal (immunology), Antibodies, Neutralizing (administration & dosage), Antibodies, Neutralizing (immunology), Antibodies, Viral (administration & dosage), Antibodies, Viral (immunology), Callithrix, Coronavirus Infections (prevention & control), Disease Models, Animal, Humans, Lung (drug effects), Lung (pathology), Lung (virology), Middle East Respiratory Syndrome Coronavirus.
- MESH :
- chemical , administration & dosage : Antibodies, Monoclonal, Antibodies, Neutralizing, Antibodies, Viral.
- chemical , immunology : Antibodies, Monoclonal, Antibodies, Neutralizing, Antibodies, Viral.
- drug effects : Lung.
- pathology : Lung.
- prevention & control : Coronavirus Infections.
- virology : Lung.
- Administration, Intravenous, Animals, Callithrix, Disease Models, Animal, Humans, Middle East Respiratory Syndrome Coronavirus.
Abstract
Effective antiviral treatments for MERS-CoV are urgently needed. LCA60 is a MERS-CoV-neutralizing monoclonal antibody isolated from a convalescent MERS patient. Previously, it was shown that treatment with LCA60 resulted in reduced disease and virus titers in mouse models of MERS-CoV infection. Here, we tested the prophylactic efficacy of LCA60 in the common marmoset model of MERS-CoV infection. Intravenous administration of LCA60 one day before virus challenge resulted in high levels of MERS-CoV-neutralizing activity in circulating blood. Clinically, there was a moderate benefit of treatment with LCA60 including reduced respiratory involvement. Although viral lung loads were not reduced in LCA60-treated animals as compared to controls, there were fewer pathological changes in the lungs. Thus, prophylactic LCA60 treatment could be implemented to reduce disease burden in contacts of confirmed MERS-CoV patients.
DOI: 10.1016/j.antiviral.2019.01.016
PubMed: 30684561
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:30684561Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Prophylactic efficacy of a human monoclonal antibody against MERS-CoV in the common marmoset.</title>
<author><name sortKey="De Wit, Emmie" sort="De Wit, Emmie" uniqKey="De Wit E" first="Emmie" last="De Wit">Emmie De Wit</name>
<affiliation wicri:level="2"><nlm:affiliation>Laboratory of Virology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Laboratory of Virology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT</wicri:regionArea>
<placeName><region type="state">Montana</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Feldmann, Friederike" sort="Feldmann, Friederike" uniqKey="Feldmann F" first="Friederike" last="Feldmann">Friederike Feldmann</name>
<affiliation wicri:level="2"><nlm:affiliation>Rocky Mountain Veterinary Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Rocky Mountain Veterinary Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT</wicri:regionArea>
<placeName><region type="state">Montana</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Horne, Eva" sort="Horne, Eva" uniqKey="Horne E" first="Eva" last="Horne">Eva Horne</name>
<affiliation wicri:level="2"><nlm:affiliation>Laboratory of Virology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Laboratory of Virology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT</wicri:regionArea>
<placeName><region type="state">Montana</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Okumura, Atsushi" sort="Okumura, Atsushi" uniqKey="Okumura A" first="Atsushi" last="Okumura">Atsushi Okumura</name>
<affiliation wicri:level="4"><nlm:affiliation>Center for Infection and Immunity, Mailman School of Public Health, Columbia University, New York, NY, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Center for Infection and Immunity, Mailman School of Public Health, Columbia University, New York, NY</wicri:regionArea>
<placeName><region type="state">État de New York</region>
<settlement type="city">New York</settlement>
</placeName>
<orgName type="university">Université Columbia</orgName>
</affiliation>
</author>
<author><name sortKey="Cameroni, Elisabetta" sort="Cameroni, Elisabetta" uniqKey="Cameroni E" first="Elisabetta" last="Cameroni">Elisabetta Cameroni</name>
<affiliation wicri:level="1"><nlm:affiliation>Humabs BioMed SA, A Subsidiary of Vir Biotechnology, 6500, Bellinzona, Switzerland.</nlm:affiliation>
<country xml:lang="fr">Suisse</country>
<wicri:regionArea>Humabs BioMed SA, A Subsidiary of Vir Biotechnology, 6500, Bellinzona</wicri:regionArea>
<wicri:noRegion>Bellinzona</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Haddock, Elaine" sort="Haddock, Elaine" uniqKey="Haddock E" first="Elaine" last="Haddock">Elaine Haddock</name>
<affiliation wicri:level="2"><nlm:affiliation>Laboratory of Virology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Laboratory of Virology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT</wicri:regionArea>
<placeName><region type="state">Montana</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Saturday, Greg" sort="Saturday, Greg" uniqKey="Saturday G" first="Greg" last="Saturday">Greg Saturday</name>
<affiliation wicri:level="2"><nlm:affiliation>Rocky Mountain Veterinary Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Rocky Mountain Veterinary Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT</wicri:regionArea>
<placeName><region type="state">Montana</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Scott, Dana" sort="Scott, Dana" uniqKey="Scott D" first="Dana" last="Scott">Dana Scott</name>
<affiliation wicri:level="2"><nlm:affiliation>Rocky Mountain Veterinary Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Rocky Mountain Veterinary Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT</wicri:regionArea>
<placeName><region type="state">Montana</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Gopal, Robin" sort="Gopal, Robin" uniqKey="Gopal R" first="Robin" last="Gopal">Robin Gopal</name>
<affiliation wicri:level="1"><nlm:affiliation>National Infection Service, Public Health England (PHE), London, NW9 5EQ, United Kingdom.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>National Infection Service, Public Health England (PHE), London, NW9 5EQ</wicri:regionArea>
<wicri:noRegion>NW9 5EQ</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Zambon, Maria" sort="Zambon, Maria" uniqKey="Zambon M" first="Maria" last="Zambon">Maria Zambon</name>
<affiliation wicri:level="1"><nlm:affiliation>National Infection Service, Public Health England (PHE), London, NW9 5EQ, United Kingdom.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>National Infection Service, Public Health England (PHE), London, NW9 5EQ</wicri:regionArea>
<wicri:noRegion>NW9 5EQ</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Corti, Davide" sort="Corti, Davide" uniqKey="Corti D" first="Davide" last="Corti">Davide Corti</name>
<affiliation wicri:level="1"><nlm:affiliation>Humabs BioMed SA, A Subsidiary of Vir Biotechnology, 6500, Bellinzona, Switzerland.</nlm:affiliation>
<country xml:lang="fr">Suisse</country>
<wicri:regionArea>Humabs BioMed SA, A Subsidiary of Vir Biotechnology, 6500, Bellinzona</wicri:regionArea>
<wicri:noRegion>Bellinzona</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Feldmann, Heinz" sort="Feldmann, Heinz" uniqKey="Feldmann H" first="Heinz" last="Feldmann">Heinz Feldmann</name>
<affiliation wicri:level="2"><nlm:affiliation>Laboratory of Virology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, USA. Electronic address: feldmannh@niaid.nih.gov.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Laboratory of Virology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT</wicri:regionArea>
<placeName><region type="state">Montana</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2019">2019</date>
<idno type="RBID">pubmed:30684561</idno>
<idno type="pmid">30684561</idno>
<idno type="doi">10.1016/j.antiviral.2019.01.016</idno>
<idno type="wicri:Area/PubMed/Corpus">000659</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000659</idno>
<idno type="wicri:Area/PubMed/Curation">000659</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000659</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000414</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000414</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Prophylactic efficacy of a human monoclonal antibody against MERS-CoV in the common marmoset.</title>
<author><name sortKey="De Wit, Emmie" sort="De Wit, Emmie" uniqKey="De Wit E" first="Emmie" last="De Wit">Emmie De Wit</name>
<affiliation wicri:level="2"><nlm:affiliation>Laboratory of Virology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Laboratory of Virology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT</wicri:regionArea>
<placeName><region type="state">Montana</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Feldmann, Friederike" sort="Feldmann, Friederike" uniqKey="Feldmann F" first="Friederike" last="Feldmann">Friederike Feldmann</name>
<affiliation wicri:level="2"><nlm:affiliation>Rocky Mountain Veterinary Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Rocky Mountain Veterinary Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT</wicri:regionArea>
<placeName><region type="state">Montana</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Horne, Eva" sort="Horne, Eva" uniqKey="Horne E" first="Eva" last="Horne">Eva Horne</name>
<affiliation wicri:level="2"><nlm:affiliation>Laboratory of Virology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Laboratory of Virology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT</wicri:regionArea>
<placeName><region type="state">Montana</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Okumura, Atsushi" sort="Okumura, Atsushi" uniqKey="Okumura A" first="Atsushi" last="Okumura">Atsushi Okumura</name>
<affiliation wicri:level="4"><nlm:affiliation>Center for Infection and Immunity, Mailman School of Public Health, Columbia University, New York, NY, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Center for Infection and Immunity, Mailman School of Public Health, Columbia University, New York, NY</wicri:regionArea>
<placeName><region type="state">État de New York</region>
<settlement type="city">New York</settlement>
</placeName>
<orgName type="university">Université Columbia</orgName>
</affiliation>
</author>
<author><name sortKey="Cameroni, Elisabetta" sort="Cameroni, Elisabetta" uniqKey="Cameroni E" first="Elisabetta" last="Cameroni">Elisabetta Cameroni</name>
<affiliation wicri:level="1"><nlm:affiliation>Humabs BioMed SA, A Subsidiary of Vir Biotechnology, 6500, Bellinzona, Switzerland.</nlm:affiliation>
<country xml:lang="fr">Suisse</country>
<wicri:regionArea>Humabs BioMed SA, A Subsidiary of Vir Biotechnology, 6500, Bellinzona</wicri:regionArea>
<wicri:noRegion>Bellinzona</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Haddock, Elaine" sort="Haddock, Elaine" uniqKey="Haddock E" first="Elaine" last="Haddock">Elaine Haddock</name>
<affiliation wicri:level="2"><nlm:affiliation>Laboratory of Virology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Laboratory of Virology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT</wicri:regionArea>
<placeName><region type="state">Montana</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Saturday, Greg" sort="Saturday, Greg" uniqKey="Saturday G" first="Greg" last="Saturday">Greg Saturday</name>
<affiliation wicri:level="2"><nlm:affiliation>Rocky Mountain Veterinary Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Rocky Mountain Veterinary Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT</wicri:regionArea>
<placeName><region type="state">Montana</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Scott, Dana" sort="Scott, Dana" uniqKey="Scott D" first="Dana" last="Scott">Dana Scott</name>
<affiliation wicri:level="2"><nlm:affiliation>Rocky Mountain Veterinary Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Rocky Mountain Veterinary Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT</wicri:regionArea>
<placeName><region type="state">Montana</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Gopal, Robin" sort="Gopal, Robin" uniqKey="Gopal R" first="Robin" last="Gopal">Robin Gopal</name>
<affiliation wicri:level="1"><nlm:affiliation>National Infection Service, Public Health England (PHE), London, NW9 5EQ, United Kingdom.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>National Infection Service, Public Health England (PHE), London, NW9 5EQ</wicri:regionArea>
<wicri:noRegion>NW9 5EQ</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Zambon, Maria" sort="Zambon, Maria" uniqKey="Zambon M" first="Maria" last="Zambon">Maria Zambon</name>
<affiliation wicri:level="1"><nlm:affiliation>National Infection Service, Public Health England (PHE), London, NW9 5EQ, United Kingdom.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>National Infection Service, Public Health England (PHE), London, NW9 5EQ</wicri:regionArea>
<wicri:noRegion>NW9 5EQ</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Corti, Davide" sort="Corti, Davide" uniqKey="Corti D" first="Davide" last="Corti">Davide Corti</name>
<affiliation wicri:level="1"><nlm:affiliation>Humabs BioMed SA, A Subsidiary of Vir Biotechnology, 6500, Bellinzona, Switzerland.</nlm:affiliation>
<country xml:lang="fr">Suisse</country>
<wicri:regionArea>Humabs BioMed SA, A Subsidiary of Vir Biotechnology, 6500, Bellinzona</wicri:regionArea>
<wicri:noRegion>Bellinzona</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Feldmann, Heinz" sort="Feldmann, Heinz" uniqKey="Feldmann H" first="Heinz" last="Feldmann">Heinz Feldmann</name>
<affiliation wicri:level="2"><nlm:affiliation>Laboratory of Virology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, USA. Electronic address: feldmannh@niaid.nih.gov.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Laboratory of Virology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT</wicri:regionArea>
<placeName><region type="state">Montana</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">Antiviral research</title>
<idno type="eISSN">1872-9096</idno>
<imprint><date when="2019" type="published">2019</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Administration, Intravenous</term>
<term>Animals</term>
<term>Antibodies, Monoclonal (administration & dosage)</term>
<term>Antibodies, Monoclonal (immunology)</term>
<term>Antibodies, Neutralizing (administration & dosage)</term>
<term>Antibodies, Neutralizing (immunology)</term>
<term>Antibodies, Viral (administration & dosage)</term>
<term>Antibodies, Viral (immunology)</term>
<term>Callithrix</term>
<term>Coronavirus Infections (prevention & control)</term>
<term>Disease Models, Animal</term>
<term>Humans</term>
<term>Lung (drug effects)</term>
<term>Lung (pathology)</term>
<term>Lung (virology)</term>
<term>Middle East Respiratory Syndrome Coronavirus</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Administration par voie intraveineuse</term>
<term>Animaux</term>
<term>Anticorps antiviraux (administration et posologie)</term>
<term>Anticorps antiviraux (immunologie)</term>
<term>Anticorps monoclonaux (administration et posologie)</term>
<term>Anticorps monoclonaux (immunologie)</term>
<term>Anticorps neutralisants (administration et posologie)</term>
<term>Anticorps neutralisants (immunologie)</term>
<term>Callithrix</term>
<term>Coronavirus du syndrome respiratoire du Moyen-Orient</term>
<term>Humains</term>
<term>Infections à coronavirus ()</term>
<term>Modèles animaux de maladie humaine</term>
<term>Poumon ()</term>
<term>Poumon (anatomopathologie)</term>
<term>Poumon (virologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antibodies, Monoclonal</term>
<term>Antibodies, Neutralizing</term>
<term>Antibodies, Viral</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antibodies, Monoclonal</term>
<term>Antibodies, Neutralizing</term>
<term>Antibodies, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Anticorps antiviraux</term>
<term>Anticorps monoclonaux</term>
<term>Anticorps neutralisants</term>
</keywords>
<keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Poumon</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Lung</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Anticorps antiviraux</term>
<term>Anticorps monoclonaux</term>
<term>Anticorps neutralisants</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Lung</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Coronavirus Infections</term>
</keywords>
<keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Poumon</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Lung</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Administration, Intravenous</term>
<term>Animals</term>
<term>Callithrix</term>
<term>Disease Models, Animal</term>
<term>Humans</term>
<term>Middle East Respiratory Syndrome Coronavirus</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Administration par voie intraveineuse</term>
<term>Animaux</term>
<term>Callithrix</term>
<term>Coronavirus du syndrome respiratoire du Moyen-Orient</term>
<term>Humains</term>
<term>Infections à coronavirus</term>
<term>Modèles animaux de maladie humaine</term>
<term>Poumon</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Effective antiviral treatments for MERS-CoV are urgently needed. LCA60 is a MERS-CoV-neutralizing monoclonal antibody isolated from a convalescent MERS patient. Previously, it was shown that treatment with LCA60 resulted in reduced disease and virus titers in mouse models of MERS-CoV infection. Here, we tested the prophylactic efficacy of LCA60 in the common marmoset model of MERS-CoV infection. Intravenous administration of LCA60 one day before virus challenge resulted in high levels of MERS-CoV-neutralizing activity in circulating blood. Clinically, there was a moderate benefit of treatment with LCA60 including reduced respiratory involvement. Although viral lung loads were not reduced in LCA60-treated animals as compared to controls, there were fewer pathological changes in the lungs. Thus, prophylactic LCA60 treatment could be implemented to reduce disease burden in contacts of confirmed MERS-CoV patients.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">30684561</PMID>
<DateCompleted><Year>2020</Year>
<Month>03</Month>
<Day>13</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>04</Month>
<Day>07</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-9096</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>163</Volume>
<PubDate><Year>2019</Year>
<Month>03</Month>
</PubDate>
</JournalIssue>
<Title>Antiviral research</Title>
<ISOAbbreviation>Antiviral Res.</ISOAbbreviation>
</Journal>
<ArticleTitle>Prophylactic efficacy of a human monoclonal antibody against MERS-CoV in the common marmoset.</ArticleTitle>
<Pagination><MedlinePgn>70-74</MedlinePgn>
</Pagination>
<ELocationID EIdType="pii" ValidYN="Y">S0166-3542(19)30036-1</ELocationID>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.antiviral.2019.01.016</ELocationID>
<Abstract><AbstractText>Effective antiviral treatments for MERS-CoV are urgently needed. LCA60 is a MERS-CoV-neutralizing monoclonal antibody isolated from a convalescent MERS patient. Previously, it was shown that treatment with LCA60 resulted in reduced disease and virus titers in mouse models of MERS-CoV infection. Here, we tested the prophylactic efficacy of LCA60 in the common marmoset model of MERS-CoV infection. Intravenous administration of LCA60 one day before virus challenge resulted in high levels of MERS-CoV-neutralizing activity in circulating blood. Clinically, there was a moderate benefit of treatment with LCA60 including reduced respiratory involvement. Although viral lung loads were not reduced in LCA60-treated animals as compared to controls, there were fewer pathological changes in the lungs. Thus, prophylactic LCA60 treatment could be implemented to reduce disease burden in contacts of confirmed MERS-CoV patients.</AbstractText>
<CopyrightInformation>Copyright © 2019. Published by Elsevier B.V.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>de Wit</LastName>
<ForeName>Emmie</ForeName>
<Initials>E</Initials>
<AffiliationInfo><Affiliation>Laboratory of Virology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Feldmann</LastName>
<ForeName>Friederike</ForeName>
<Initials>F</Initials>
<AffiliationInfo><Affiliation>Rocky Mountain Veterinary Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Horne</LastName>
<ForeName>Eva</ForeName>
<Initials>E</Initials>
<AffiliationInfo><Affiliation>Laboratory of Virology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Okumura</LastName>
<ForeName>Atsushi</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Center for Infection and Immunity, Mailman School of Public Health, Columbia University, New York, NY, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Cameroni</LastName>
<ForeName>Elisabetta</ForeName>
<Initials>E</Initials>
<AffiliationInfo><Affiliation>Humabs BioMed SA, A Subsidiary of Vir Biotechnology, 6500, Bellinzona, Switzerland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Haddock</LastName>
<ForeName>Elaine</ForeName>
<Initials>E</Initials>
<AffiliationInfo><Affiliation>Laboratory of Virology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Saturday</LastName>
<ForeName>Greg</ForeName>
<Initials>G</Initials>
<AffiliationInfo><Affiliation>Rocky Mountain Veterinary Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Scott</LastName>
<ForeName>Dana</ForeName>
<Initials>D</Initials>
<AffiliationInfo><Affiliation>Rocky Mountain Veterinary Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Gopal</LastName>
<ForeName>Robin</ForeName>
<Initials>R</Initials>
<AffiliationInfo><Affiliation>National Infection Service, Public Health England (PHE), London, NW9 5EQ, United Kingdom.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Zambon</LastName>
<ForeName>Maria</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>National Infection Service, Public Health England (PHE), London, NW9 5EQ, United Kingdom.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Corti</LastName>
<ForeName>Davide</ForeName>
<Initials>D</Initials>
<AffiliationInfo><Affiliation>Humabs BioMed SA, A Subsidiary of Vir Biotechnology, 6500, Bellinzona, Switzerland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Feldmann</LastName>
<ForeName>Heinz</ForeName>
<Initials>H</Initials>
<AffiliationInfo><Affiliation>Laboratory of Virology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, USA. Electronic address: feldmannh@niaid.nih.gov.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType>
<PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2019</Year>
<Month>01</Month>
<Day>24</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>Netherlands</Country>
<MedlineTA>Antiviral Res</MedlineTA>
<NlmUniqueID>8109699</NlmUniqueID>
<ISSNLinking>0166-3542</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D061605" MajorTopicYN="N">Administration, Intravenous</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002144" MajorTopicYN="N">Callithrix</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName>
<QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008168" MajorTopicYN="N">Lung</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D065207" MajorTopicYN="Y">Middle East Respiratory Syndrome Coronavirus</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Common marmoset</Keyword>
<Keyword MajorTopicYN="Y">LCA60</Keyword>
<Keyword MajorTopicYN="Y">MERS-CoV</Keyword>
<Keyword MajorTopicYN="Y">Neutralizing monoclonal antibody</Keyword>
<Keyword MajorTopicYN="Y">Prophylaxis</Keyword>
<Keyword MajorTopicYN="Y">Treatment</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year>
<Month>01</Month>
<Day>21</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2019</Year>
<Month>01</Month>
<Day>23</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2019</Year>
<Month>1</Month>
<Day>27</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>3</Month>
<Day>14</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2019</Year>
<Month>1</Month>
<Day>27</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">30684561</ArticleId>
<ArticleId IdType="pii">S0166-3542(19)30036-1</ArticleId>
<ArticleId IdType="doi">10.1016/j.antiviral.2019.01.016</ArticleId>
<ArticleId IdType="pmc">PMC7113761</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>J Infect Dis. 2015 Dec 15;212(12):1904-13</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26198719</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Antiviral Res. 2017 Jul;143:30-37</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28389142</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Nat Med. 2013 Oct;19(10):1313-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24013700</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Euro Surveill. 2012 Sep 27;17(39):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23041020</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Infect Dis. 2017 Jun 15;215(12):1807-1815</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28472421</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>PLoS Pathog. 2014 Aug 21;10(8):e1004250</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25144235</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Euro Surveill. 2012 Oct 04;17(40):20290</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23078800</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Antiviral Res. 2016 Aug;132:141-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27312105</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2013 Oct 8;110(41):16598-603</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24062443</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Vet Pathol. 2016 May;53(3):521-31</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26869154</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Cell Res. 2015 Nov;25(11):1237-49</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26391698</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Sci Rep. 2016 Aug 19;6:31629</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27538452</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2015 Aug 18;112(33):10473-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26216974</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Infect Public Health. 2016 May-Jun;9(3):231-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27102927</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2015 Jul 14;112(28):8738-43</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26124093</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Virology. 2016 Mar;490:49-58</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26828465</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Nature. 2013 Sep 19;501(7467):439-43</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23955151</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2018 Aug 29;92(18):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29950421</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Antiviral Res. 2018 Aug;156:64-71</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29885377</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Royaume-Uni</li>
<li>Suisse</li>
<li>États-Unis</li>
</country>
<region><li>Montana</li>
<li>État de New York</li>
</region>
<settlement><li>New York</li>
</settlement>
<orgName><li>Université Columbia</li>
</orgName>
</list>
<tree><country name="États-Unis"><region name="Montana"><name sortKey="De Wit, Emmie" sort="De Wit, Emmie" uniqKey="De Wit E" first="Emmie" last="De Wit">Emmie De Wit</name>
</region>
<name sortKey="Feldmann, Friederike" sort="Feldmann, Friederike" uniqKey="Feldmann F" first="Friederike" last="Feldmann">Friederike Feldmann</name>
<name sortKey="Feldmann, Heinz" sort="Feldmann, Heinz" uniqKey="Feldmann H" first="Heinz" last="Feldmann">Heinz Feldmann</name>
<name sortKey="Haddock, Elaine" sort="Haddock, Elaine" uniqKey="Haddock E" first="Elaine" last="Haddock">Elaine Haddock</name>
<name sortKey="Horne, Eva" sort="Horne, Eva" uniqKey="Horne E" first="Eva" last="Horne">Eva Horne</name>
<name sortKey="Okumura, Atsushi" sort="Okumura, Atsushi" uniqKey="Okumura A" first="Atsushi" last="Okumura">Atsushi Okumura</name>
<name sortKey="Saturday, Greg" sort="Saturday, Greg" uniqKey="Saturday G" first="Greg" last="Saturday">Greg Saturday</name>
<name sortKey="Scott, Dana" sort="Scott, Dana" uniqKey="Scott D" first="Dana" last="Scott">Dana Scott</name>
</country>
<country name="Suisse"><noRegion><name sortKey="Cameroni, Elisabetta" sort="Cameroni, Elisabetta" uniqKey="Cameroni E" first="Elisabetta" last="Cameroni">Elisabetta Cameroni</name>
</noRegion>
<name sortKey="Corti, Davide" sort="Corti, Davide" uniqKey="Corti D" first="Davide" last="Corti">Davide Corti</name>
</country>
<country name="Royaume-Uni"><noRegion><name sortKey="Gopal, Robin" sort="Gopal, Robin" uniqKey="Gopal R" first="Robin" last="Gopal">Robin Gopal</name>
</noRegion>
<name sortKey="Zambon, Maria" sort="Zambon, Maria" uniqKey="Zambon M" first="Maria" last="Zambon">Maria Zambon</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000414 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000414 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= MersV1 |flux= PubMed |étape= Checkpoint |type= RBID |clé= pubmed:30684561 |texte= Prophylactic efficacy of a human monoclonal antibody against MERS-CoV in the common marmoset. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:30684561" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \ | NlmPubMed2Wicri -a MersV1
This area was generated with Dilib version V0.6.33. |